Cash-flow figures use the latest fiscal year: this filer tags quarterly cash flows year-to-date only and the missing discrete quarters could not be derived (irregular fiscal quarters or a tagging change), so no four consecutive quarters exist to sum.
No four consecutive quarters could be summed for Interest Expense; these figures use the latest fiscal year, not a trailing twelve months.
full derived coverage requires a plan
Output of a disclosed model — assumptions may be wrong. Research, not investment advice. See the Disclaimer.
— Months · distinct values (the real sample size).
Metric
Today
Own median
Own range
%ile
z
Sector med.
mo · distinct
P/E
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
−104.3%
−59.3%
28th
−0.95σ
−36.9%
63 · 6
−95.5%
−76.1%
9th
−1.07σ
−15.4%
63 · 6
−560.3%
−966.5%
75th
+0.63σ
−21.3%
74 · 6
−25.6%
−9.4%
48th
−0.22σ
5.1%
141 · 140
EPS Growth 3Y
—
P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
47.4%
—
no band (38 mo · 3 distinct)
—
—
9.0%
38 · 3
Market Cap
$29.40M
not reconstructed — market cap was removed from the historical pass (never a ranking factor, and a reconstructed share count carries look-ahead risk). The single stored value is the forward-captured snapshot, not a series.
ROE (point-in-time)Health Care median, same monthshaded = own p10–p90 · dashed = own median · right-edge tick = today
Multiple-implied price ladder · Full
Filed earnings only.
no P/E ladder — P/E and EPS growth are reconstructed for US-domestic 10-K filers only — a 20-F/40-F foreign private issuer's ADR trades in USD while its EPS is reported in the native currency, so no multiple is reconstructed rather than a wrong one.
Ladder not drawn for this name — the reason is above.ⓘ
Not a forecast: each row re-prices today's filed earnings at a multiple this company itself once traded at. It abstains rather than guess on a loss year or a broken per-share basis.
Every month uses only what was filed by then, split-adjusted. Delisted names are absent and a trough year can throw one huge reading, so read the median, not the edges.
Percentile through time (point-in-time cohort)
Loading the monthly cohort placement…
▸Comp setname your own peers — pick a pool or add tickers
Covered pool$937.70B +7.6%/yr 2020→2025Concentration456 of 10,000fragmented · top 3 hold 23.1% · −151 pts since 2019IGC0.0% · rank 319 of 385 · −0.0pp over 5y· CV 0.98 · σ 0.0pp
Who holds the poolCY2025 · bars scaled to the largest member
IGC is not drawn here: its newest pool year (CY2024) differs from the industry’s (CY2025), so its 0.0% is a different year’s share.
Growth, restated as sharewhere each pace has to END UP, by 2029
Its own realised pace0.0% → 0.0%
The pace the price requires— The growth today's price requires (our reverse-DCF) is a Pro metric — the realized-pace runway above is free.
IGC share over time6 published years
Calendar year
2019
2020
2021
2022
2023
2024
Share of covered pool
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
year: this company's newest published… · coverage: 346 of the 377 members that…
Share of covered industry revenue · n=385 in Pharmaceuticals & Biotechnology · CY2024 pool · built 2026-08-19 not market shareⓘ
Covered filers only, not market share — private and uncovered companies are missing, so every share here reads high. Years are FX-converted and published only once most of the pool has filed.
